$49 per month*
Subscribe to Pro or Enterprise plans to unlock this feature.
Become a smarter investor today.
Become a smarter investor today.
This statistic highlights Gilead Sciences’ Revenue Breakdown Worldwide, split between Europe, Other International, and United States, reported on a quarterly basis from Q1 2016 onwards.
Gilead Sciences, Inc. is a biopharmaceutical company that has spent more than three decades pursuing and achieving medical discoveries to make the world a healthier place for everyone. Harvoni and Sovaldi are two antiviral medicines developed by the company, which are used to treat HIV, hepatitis B, hepatitis C, and influenza. The company’s new medications reflect improvements by providing first-class therapies, increased effectiveness, improved routes of delivery, more convenient treatment regimes, improved resistance profiles, and decreased adverse effects. In addition, the company’s focus on innovation has allowed by providing marketed goods in a variety of therapeutic areas.
Gilead Sciences, Inc. generates its revenue from the following regions:
The following table sheds more light on each of the region and their contribution to the company’s overall top line.
|Region||Q1 2020||Q1 2021||YOY Growth||Revenue Share in Q1 2021|
(All figures in millions, except percentages)
Gilead Sciences, Inc.’s total revenue rose from $5,468 million in Q1 2020 to $6,427 million in Q1 2021, marking an increase of 17.54% on a year-on-year basis.
Gilead Sciences, Inc. generates its revenue from different segments like Viread, Truvada, Emtriva, HIV products, AmBisome, Atripla, Letairis, Ranexa, Complete Eviplera, Stribild, Sovaldi, and Harvoni. These are the products of the company.
Gilead Sciences’ revenue from the Europe region increased from $927 million in Q1 2020 to $1340 million in Q1 2021, marking an increase of 44.55% on a year-on-year basis. During this period, this region contributed 20.85% to the company’s total revenue. Gilead and the European Union have agreed to a six-month joint procurement agreement that will cover Veklury purchases until April 2021. Product sales in Europe grew by 9% in 2020, owing largely to Veklury sales and continuing patient adoption of Biktarvy and Yescarta. This is a key revenue generator for the company.
Gilead Sciences’ revenue from the Other International regions rose from $551 million in Q1 2020 to $827 million in Q1 2021, marking an increase of approximately 50% on a year-on-year basis. In Q1 2021, this region contributed 12.87% to Gilead Sciences’ total revenue. This revenue growth was primarily due to higher sales volumes of Biktarvy, Veklury, and Vemlidy. product sales in this region increased by 17%.
Gilead Sciences’ revenue from the United States increased from $$3,990 million in Q1 2020 to $4,260 million in Q1 2021, marking an increase of 6.77% on a year-on-year basis. During this period, this region contributed 66.28% to the company’s total revenue.
Gilead Sciences, Inc. is a biopharmaceutical company established in 1987 by Michael L. Riordan. It is headquartered in Foster City, California, United States. Daniel O’Day is the current Chairman and CEO of the company. The company operates in more than 35 countries worldwide. The company faces tough competition from Vertex, Genentech, Cipla, Bristol-Myers Squibb, Biogen, Amgen, and Jazz Pharmaceuticals. Gilead Sciences is traded on the Nasdaq stock exchange in 1992 under the ticker code “GILD”.
Gilead Sciences has acquired Nexstar Pharmaceuticals, Myogen, Immunomedics, MYR GmbH, and Kite Pharma until 2020. The company has 11,800 employees worldwide.
Did you like Gilead Sciences’ Revenue Breakdown Worldwide statistic?
Access thousands of more such key performance indicator data points, on listed companies, with Business Quant.
You can also get started for free.
Always know what you’ll pay. No hidden costs or surprises.
* Billed annually, local taxes extra.
* Local taxes extra.